Implantation and imaging of BioXmark- and Gold-Markers in resection specimen of patients with adenocarcinoma of the pancreas

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009725

Enrollment

Registered

2016-01-05

Start date

2017-03-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C25.9

Interventions

Group 1: Implantation of the markers (BioXmark, gold marker) in resection specimen of patients with primary resectable adenocarcinoma of the pancreas

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients with primary resectable adenocarcinoma of the pancreas undergoing oncologic surgery - oral and written consent

Exclusion criteria

Exclusion criteria: - neoadjuvant therapy e.g. chemotherapy

Design outcomes

Primary

Measure	Time frame
Feasibility to implant both markers (BioXmark, gold marker)	—

Secondary

Measure	Time frame
Visibility of both markers on CT, MRI and kV/MV-x-ray imaging, Reliable pathologic assessment of the resection specimen after implantation of the markers	—

Countries

Germany

Contacts

Public ContactAnnett Klöber

Universitätsklinikum Dresden, Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinisches Studienzentrum

str.studien@uniklinikum-dresden.de0351-458 13390

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026